Anti-cancer effects of MW-03, a novel indole compound, by inducing 15-hydroxyprostaglandin dehydrogenase and cellular growth inhibition in the ls174t human colon cancer cell line

Naofumi Seira, Naoki Yanagisawa, Akiko Suganami, Takuya Honda, Makiko Wasai, John W Regan, Keijo Fukushima, Naoto Yamaguchi, Yutaka Tamura, Takayoshi Arai, Toshihiko Murayama, Hiromichi Fujino

Research output: Contribution to journalArticle

1 Scopus citations


Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.

Original languageEnglish (US)
Pages (from-to)1806-1812
Number of pages7
JournalBiological and Pharmaceutical Bulletin
Issue number10
Publication statusPublished - 2017



  • 15-hydroxyprostaglandin dehydrogenase
  • Colon cancer
  • Indole compound
  • MW-03
  • Peroxisome proliferator-activated receptor-γ
  • Prostaglandin E2

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this